Skip to content

Overthrive

Active Risk: not assessed
Private limited companyfounded 2023active for 3 yearsErnestinelaan 2, 1050 Elsene, Belgium21 active companies are registered at this addressKBO/BCE: BE 0800.628.793
Summary

Overthrive is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €37,033 and a net result of €17,420. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 31% of 9,643 sector peers (NACE 64, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.

History

Overthrive was incorporated on 11 April 2023 as a private limited company.1 The registered office was moved to Elsene in 2026.2 Total assets rose from €47,101 in 2023 to €131,809 in 2025.3

  1. 1KBO (Crossroads Bank for Enterprises)
  2. 2Belgian Official Gazette, 16-06-2026
  3. 3National Bank, annual accounts 2023 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
26-06
NBB filing Annual accounts filed
financial year 2025 · micro format
16-06
Gazette deed Permanent representative: Isabel Walcarius
Registered-office move3 facts ▸
  • Board meeting, 23-02-2026
  • Registered-office move, Ermestinelaan 2 bus 14, 1050 Elsene
  • Permanent representative, Isabel Walcarius
2025
11-09
NBB filing Annual accounts filed
financial year 2024 · micro format · 42 days late
2024
31-12
Financial Weakest financial yearnet €16,739 ▼37.7%
Net result drops to €16,739, the lowest in the series; recovery starts the following year.
24-09
NBB filing Annual accounts filed
financial year 2023 · micro format · 55 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 2 deeds read
About the unread acts

Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.